What To Know About Barclays's Downgrade of CME Gr
Portfolio Pulse from Benzinga Insights
Barclays has downgraded CME Group (NASDAQ:CME) from an Overweight to an Equal-Weight rating and lowered the price target from $244.00 to $222.00. CME Group's shares are currently trading at $198.87, which is a 0.16% decrease over the last 24 hours. The new price target suggests a potential upside of 11.63% from the current share price. CME Group, based in Chicago, is a leading derivatives marketplace and has a significant stake in S&P Dow Jones Indices.
January 08, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays downgraded CME Group to Equal-Weight and reduced the price target from $244.00 to $222.00. The current trading price is $198.87, with the new target representing an 11.63% potential increase.
The downgrade by Barclays is a significant change in the analyst's view of CME Group's stock, which could influence investor sentiment and potentially lead to short-term price fluctuations. However, the new price target still suggests an upside, indicating that the downgrade is not necessarily a bearish signal but rather a moderation of expectations. The confidence level is high due to the clear information provided by a reputable financial institution, but not at 100 because market reactions can be unpredictable.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100